{
  "schemaVersion": "2.1",
  "datasetVersion": "2026-09-11.1",
  "generatedAt": "2026-09-11",
  "reviewStatus": "Editorial source review is complete. This edition has not been independently medically reviewed.",
  "editorialBoundary": "Source-checked educational summaries. Topics require evidence and editorial review. This dataset is not a personal treatment plan.",
  "citation": "When you cite a record, include The Peptide Field, its canonicalPath, this dataset version, and every source used for the claim.",
  "reuse": "This endpoint grants no additional reuse license. Keep the verdict, scope, evidence basis, review date, and source links together. Do not present a record as medical advice or medical review.",
  "changeLogPath": "/corrections#correction-ledger",
  "contactPath": "/corrections",
  "dataset": "peptide-evidence-checker-record",
  "canonicalPath": "/peptides/tb-500",
  "canonicalUrl": "https://thepeptidefield.com/peptides/tb-500",
  "record": {
    "slug": "tb-500",
    "name": "TB-500",
    "aliases": [
      "TB500",
      "Ac-LKKTETQ",
      "thymosin beta-4 fragment 17-23"
    ],
    "className": "Synthetic thymosin beta-4 fragment",
    "family": "Recovery and repair claims",
    "sequenceLabel": "7 amino acids · N-terminal acetylated fragment",
    "tier": "Insufficient",
    "evidenceContext": "Preclinical or formulation evidence",
    "statusLine": "No FDA-approved TB-500 drug product",
    "productContext": "TB-500 is not the same as the full thymosin beta-4 molecule. FDA identifies TB-500 as a seven-amino-acid fragment, not as interchangeable with full-length thymosin beta-4. Internet naming and certificates do not establish product identity or clinical equivalence.",
    "approvedProducts": [],
    "indications": [
      "No FDA-approved indication"
    ],
    "profile": {
      "humanOutcomes": {
        "level": "Unclear",
        "note": "FDA found no adequate human clinical outcome evidence for compounded TB-500 wound-healing use."
      },
      "humanPharmacology": {
        "level": "Limited",
        "note": "Fragment identity and laboratory findings do not establish a clinical benefit in people."
      },
      "safetyKnowledge": {
        "level": "Unclear",
        "note": "Human exposure and product-specific safety information are inadequate."
      },
      "productCertainty": {
        "level": "Unclear",
        "note": "Nomenclature, salt form, purity, sterility, and fragment-versus-protein distinctions create major uncertainty."
      }
    },
    "oneLine": "A seven-amino-acid piece of thymosin beta-4 promoted for repair, without reliable human healing evidence and with major product and anti-doping limits.",
    "reviewedAt": "August 1, 2026",
    "reviewedAtISO": "2026-08-01",
    "reviewHistory": [
      {
        "date": "2026-08-01",
        "note": "Revalidated TB-500 against the 2026 WADA Prohibited List, where TB-500 and thymosin-beta-4 are named in the prohibited growth-factor category."
      },
      {
        "date": "2026-07-23",
        "note": "Initial brief uses FDA's July 2026 identity and evidence review before final agency action."
      }
    ],
    "whatItIs": "TB-500 is reported as a seven-amino-acid piece, or fragment, of thymosin beta-4. It is not full-length thymosin beta-4, and evidence about the full protein cannot automatically be transferred to the fragment.",
    "whatWeKnow": "FDA has published a detailed 2026 briefing on TB-500's identity, characterization, proposed wound-healing use, and evidence gaps. WADA explicitly names TB-500 on the 2026 Prohibited List.",
    "whatWeDoNotKnow": "Reliable controlled studies in people do not establish faster tendon, muscle, or wound healing from TB-500. Safety, purity, sterility, long-term effects, and equivalence of marketed material remain uncertain.",
    "antiDoping": "TB-500 and thymosin beta-4 are named on the 2026 World Anti-Doping Agency Prohibited List.",
    "antiDopingReview": {
      "status": "Prohibited",
      "detail": "TB-500 is named as a prohibited thymosin-beta-4 derivative on the 2026 WADA Prohibited List and is prohibited at all times for covered athletes.",
      "sourceUrl": "https://www.wada-ama.org/en/resources/world-anti-doping-program/prohibited-list",
      "reviewedAtISO": "2026-08-01"
    },
    "safetyBoundary": "This is not an invitation to experiment. The guide provides no sourcing, reconstitution, injection, cycle, stack, or injury-treatment instructions.",
    "relatedSlugs": [
      "bpc-157",
      "thymosin-alpha-1",
      "ghk-cu"
    ],
    "claims": [
      {
        "claim": "“TB-500 is the same thing as thymosin beta-4.”",
        "verdict": "Misleading",
        "explanation": "FDA describes TB-500 as a seven-amino-acid fragment of the much larger thymosin beta-4 molecule.",
        "category": "Mechanism and biomarkers",
        "evidenceBasis": "Regulatory or product record",
        "scope": "Chemical identity, not a claim about all possible biological activity.",
        "sourceUrls": [
          "https://www.fda.gov/media/193349/download"
        ]
      },
      {
        "claim": "“TB-500 accelerates tendon and muscle healing in people.”",
        "verdict": "Not established",
        "explanation": "The FDA evidence review did not identify adequate human outcome evidence for wound-healing use.",
        "category": "Performance and recovery",
        "evidenceBasis": "No reliable human outcome evidence",
        "scope": "Clinical tendon, muscle, and wound-healing outcomes in people.",
        "sourceUrls": [
          "https://www.fda.gov/media/193349/download"
        ]
      },
      {
        "claim": "“TB-500 is allowed in tested sport.”",
        "verdict": "Misleading",
        "explanation": "TB-500 is named on the current WADA Prohibited List.",
        "category": "Performance and recovery",
        "evidenceBasis": "Regulatory or product record",
        "scope": "Sport governed by the World Anti-Doping Code.",
        "sourceUrls": [
          "https://www.wada-ama.org/en/resources/world-anti-doping-program/prohibited-list"
        ]
      }
    ],
    "sources": [
      {
        "label": "FDA briefing document for TB-500-related bulk drug substances",
        "publisher": "U.S. Food and Drug Administration",
        "url": "https://www.fda.gov/media/193349/download",
        "kind": "FDA review",
        "year": 2026,
        "accessedAt": "2026-07-23"
      },
      {
        "label": "TB-500 substance record",
        "publisher": "U.S. Food and Drug Administration Global Substance Registration System",
        "url": "https://precision.fda.gov/uniisearch/srs/unii/QHK6Z47GTG",
        "kind": "Reference",
        "year": 2026,
        "accessedAt": "2026-07-23"
      },
      {
        "label": "2026 Prohibited List",
        "publisher": "World Anti-Doping Agency",
        "url": "https://www.wada-ama.org/en/resources/world-anti-doping-program/prohibited-list",
        "kind": "Anti-doping",
        "year": 2026,
        "accessedAt": "2026-07-23"
      }
    ],
    "productRecords": []
  }
}